Dr. Schneider is the Chief Operating Officer for Solid Biosciences, responsible for overseeing corporate and technical operations, quality, patient advocacy, communications, corporate strategy, and human resources. As Solid’s first employee in 2014, Dr. Schneider was instrumental in discovering and executing proof-of-concept studies for SGT-001, as well as building the company’s unique disease-focused business model. In his role as Chief Operating Officer, Dr. Schneider oversees corporate and technical operations, quality, patient advocacy, communications, corporate strategy, and human resources. Dr. Schneider previously completed a postdoctoral fellowship at Harvard University in the Department of Stem Cell and Regenerative Biology, characterizing and developing small molecules that enhance skeletal muscle regeneration. He holds a Ph.D. from Rutgers University and an undergraduate degree from Brandeis University. Dr. Schneider is the author of numerous peer-reviewed articles related to Duchenne and stem cell biology.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related